This commentary suggests that the use of GLP‐1 RAs was not associated with an increased risk for incident atrial fibrillation reported as serious adverse event in individuals with type 2 diabetes who either have increased cardiovascular risk or established cardiovascular disease when compared to placebo (Diabetes/Metabolism Research and Reviews)
Diabetes News
Tag: AF
Chronic kidney disease and undiagnosed atrial fibrillation in individuals with diabetes
Among individuals with diabetes, CKD significantly increases the risk of incident AF. Identification of AF prior to clinical symptoms through active ECG screening could help to improve the clinical outcomes in individuals with CKD and diabetes (Cardiovascular Diabetology)
SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: a systematic review with meta-analysis of 16 randomized controlled trials
SGLT2 inhibitors may confer a specific AF/AFL-reduction benefit in the susceptible type 2 diabetes population, regardless of age, body weight, HbA1c, and systolic blood pressure at baseline (Cardiovascular Diabetology)
Effect of Dapagliflozin on Atrial Fibrillation in Patients with Type 2 Diabetes Mellitus: Insights from the DECLARE-TIMI 58 Trial
Dapagliflozin decreased the incidence of reported episodes of AF/AFL adverse events in high-risk patients with T2DM. This effect was consistent regardless of the patients’ prior history of AF, ASCVD, or HF (circulation)
Glycosmedia is also available as an App: